Circ-CDYL驱动的非编码调控RNA网络特异作用于早期肝细胞癌
该研究通过全基因组分析mRNA、环状RNA和microRNA表达谱,揭示早期肝细胞癌中存在以Circ-CDYL为中心的非编码调控RNA网络。Circ-CDYL在早期肝癌特异性上调,通过吸附miR-892a和miR-328-3p调控HDGF和HIF1AN,进而影响PI3K-AKT-mTORC1/β-catenin和NOTCH2通路。Circ-CDYL表达及联合HDGF和HIF1AN是鉴别早期肝癌的独立标志物,比值比分别为1.09(95%CI 1.02-1.17)和124.58(95%CI 13.26-1170.56)。
要点
- Circ-CDYL在早期肝细胞癌中特异性上调,促进EPCAM阳性肝肿瘤起始细胞特性。
- Circ-CDYL通过吸附miR-892a和miR-328-3p分别调控HDGF和HIF1AN表达。
- Circ-CDYL联合HDGF和HIF1AN鉴别早期肝癌的比值比为124.58(95%CI 13.26-1170.56)。
核心结论
- 研究揭示了早期肝细胞癌中以环状RNA为中心的非编码调控RNA网络,为肝癌监测和早期治疗提供了可能性。
研究设计与样本
- 通过全基因组分析mRNA、环状RNA和microRNA表达谱,研究早期肝细胞癌中的非编码调控RNA网络。
主要发现
- Circ-CDYL在早期肝细胞癌中特异性上调,并促进EPCAM阳性肝肿瘤起始细胞特性。
- Circ-CDYL作为miR-892a和miR-328-3p的吸附海绵,分别与编码HDGF和HIF1AN的mRNA相互作用。
- Circ-CDYL影响PI3K-AKT-mTORC1/β-catenin和NOTCH2通路的激活,促进SURVIVIN和MYC表达。
- 联合Circ-CDYL干扰与靶向PI3K和HIF1AN的传统酶抑制剂,在肝细胞癌中高效抑制干细胞样特性和肿瘤生长。
- Circ-CDYL表达及联合HDGF和HIF1AN鉴别早期肝细胞癌的比值比分别为1.09(95%CI 1.02-1.17)和124.58(95%CI 13.26-1170.56)。
关键数值与推荐
- Circ-CDYL表达鉴别早期肝细胞癌的比值比为1.09(95%CI 1.02-1.17)。
- Circ-CDYL联合HDGF和HIF1AN鉴别早期肝细胞癌的比值比为124.58(95%CI 13.26-1170.56)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is one of the fastest-rising causes of cancer-related death worldwide, but its deficiency of specific biomarkers and therapeutic targets in the early stages lead to severe inadequacy in the early diagnosis and treatment of HCC. Covalently closed circular RNA (circRNA), which was once considered an aberrant splicing by-product, is now drawing new interest in cancer research because of its remarkable functionality. Beneath the surface of the dominant functional proteins events, a hidden circRNA-centric noncoding regulatory RNAs network active in the very early stage of HCC is here revealed by a genome-wide analysis of mRNA, circRNA, and microRNA (miRNA) expression profiles. Circ-CDYL (chromodomain Y like) is specifically up-regulated in the early stages of HCC and therefore contributes to the properties of epithelial cell adhesion molecule (EPCAM)-positive liver tumor-initiating cells. Circ-CDYL interacts with mRNAs encoding hepatoma-derived growth factor (HDGF) and hypoxia-inducible factor asparagine hydroxylase (HIF1AN) by acting as the sponge of miR-892a and miR-328-3p, respectively. Subsequently, activation of the phosphoinositide 3-kinase (PI3K)-AKT serine/threonine kinase-mechanistic target of rapamycin kinase complex 1/β-catenin and NOTCH2 pathways, which promote the expression of the effect proteins, baculoviral IAP repeat containing 5 (BIRC5 or SURVIVIN) and MYC proto-oncogene, is influenced by circ-CDYL. A treatment incorporating circ-CDYL interference and traditional enzyme inhibitors targeting PI3K and HIF1AN demonstrated highly effective inhibition of stem-like characteristics and tumor growth in HCC. Finally, we demonstrated that circ-CDYL expression or which combined with HDGF and HIF1AN are both independent markers for discrimination of early stages of HCC with the odds ratios of 1.09 (95% confidence interval [CI], 1.02-1.17) and 124.58 (95% CI, 13.26-1170.56), respectively. Conclusion: These findings uncover a circRNA-centric noncoding regulatory RNAs network in the early stages of HCC and thus provide a possibility for surveillance and early treatment of HCC.
引用
- Wei Y, Chen X, Liang C, et al. A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma. Hepatology. 2019. PMID: 31148183. doi:10.1002/hep.30795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。